Sign In
Buy ALDX
$1.54
-0.0600 (-3.75%)
At Close: Jul 31, 2026
Aldeyra Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
08:00am, Thursday, 18'th Feb 2021
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will present at the 10th
Aldeyra Therapeutics Deserves A Shout Out
06:16am, Sunday, 14'th Feb 2021
Today, we are going to take an in-depth look at an ocular concern named Aldeyra Therapeutics. Shortly after positive results from the run-in cohort of a pivotal trial evaluating its lead candidate (re
Aldeyra: Reproxalap's Phase 3 Clinical Results, Expected ~75% Sales CAGR, And More
07:53pm, Monday, 18'th Jan 2021
Aldeyra Therapeutics, Inc. is a clinical-stage biotechnology company aiming to develop novel therapies for immune-mediated diseases with its lead candidate Reproxalap finishing up its Phase 3 multi-tr
3 Biotech Stocks That Jumped Last Week
09:59am, Sunday, 17'th Jan 2021
Find out what led to the biotech industry's biggest gains.
Notable Insider Buys Of The Past Week: Conagra Brands Plus Plenty Of Biotech Activity
02:22pm, Saturday, 16'th Jan 2021
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying c
Why Aldeyra Therapeutics Stock Is Jumping Today
11:25am, Thursday, 14'th Jan 2021
The company announced the pricing of a public stock offering.
Aldeyra Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock
09:36pm, Wednesday, 13'th Jan 2021
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to impro
Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock
04:01pm, Wednesday, 13'th Jan 2021
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to impro
Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect 2021 Virtual Conference
08:00am, Friday, 08'th Jan 2021
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fir
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Thursday, January 7, 2021, to discuss top-line symptom, r
Aldeyra Therapeutics Announces Confirmation of Antiviral Activity of ADX-1612
08:00am, Tuesday, 22'nd Dec 2020
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced confirmation of SARS-CoV-2 antiviral activity of ADX-1612, in addition to novel anti-inflammatory
Week 52 MDA Breakout Forecast - December: Short-Term Picks To Give You An Edge
05:47am, Sunday, 20'th Dec 2020
Week 52 MDA Breakout Forecast - December: Short-Term Picks To Give You An Edge
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the initiation of Phase 2 clinical trials of ADX-629, a first-in-class orally administered reacti
Aldeyra Announces First Patient Enrolled in the Phase 3 TRANQUILITY Trial of Reproxalap for the Treatment of Dry Eye Disease
08:00am, Tuesday, 08'th Dec 2020
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to impro
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2020 Results - Quick Version Earnings Call Transcript
10:19am, Thursday, 05'th Nov 2020
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q3 2020 Results - Quick Version Earnings Call Transcript
